Dr. Nicola Longo, MD

Dr. Longo practices at Sunrise Hospital and Medical Center in Las Vegas, Nevada, part of HCA Healthcare.

Dr. Longo's NPI, 1275612749, was assigned on November 3, 2006. Dr. Longo graduated from Univ Parma- Fac Med in 1982. Dr. Longo holds California license C196187.

Dr. Longo's primary practice is Sunrise Hospital and Medical Center, at 3186 S Maryland Pkwy, Las Vegas, NV 89109 in Clark County. The practice phone is (702) 731-8000.

Dr. Longo's primary practice is Sunrise Hospital and Medical Center in Las Vegas, Nevada, part of HCA Healthcare. Dr. Longo is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is Cure 4 The Kids Foundation. Dmand AI also links Dr. Longo to 4 more group practices and clinics and 4 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Longo practices, 6 sites in all. Vendor and product names are available with a free account.

Clinical genetics (m.d.) is Dr. Longo's primary specialty in the NPI Registry, under taxonomy code 207SG0201X. Dr. Longo is board certified in clinical biochemical genetics by the American Board of Medical Genetics and Genomics. Dmand AI has Dr. Longo's licenses on file in 6 states: California, Alaska, Utah, Nevada, Wyoming and Georgia.

CMS data shows 14 Medicare services from Dr. Longo across 1 procedure code in 2020, all of them office visits, for 11 Medicare patients. Medicare paid $1,199 for them. Every service was in an office.

CMS counts 11 Medicare patients who saw Dr. Longo in 2024. The largest group is 75 to 84, with 0 patients. Their average risk score is 2.59, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Longo's median patient age at 18, with 59% women.

In 2024, Dr. Longo wrote 45 Medicare Part D claims. 60% of them were for generic drugs. CMS names the drug for 38 of them, across 3 drugs with 11 or more claims each, at $856,989 in total drug cost. In 2023, CMS named 76 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 78 out of 100 for Dr. Longo for performance year 2024, reported as part of a group. Dr. Longo accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Longo as offering telehealth.

Dmand AI links 4 papers to Dr. Longo, published from 2018 to 2021. Dr. Longo's most frequent co-authors are Deborah A. Bilder, MD, Barbara Kay Burton, MD and Cary Owen Harding, MD.

Dmand AI links Dr. Longo to 9 clinical trials, 2 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Fabry Disease, Amino Acid Metabolism, Inborn Errors and Cerebral Small Vessel Diseases. Shire sponsors the most, 2.

CMS Open Payments shows 353 general payments to Dr. Longo from 19 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 39% of the total. BioMarin Pharmaceutical Inc. paid the most, $155,307.

Dr. Longo graduated from Univ Parma- Fac Med in 1982.

Dr. Longo is in network with 11 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.